leave out paragraph (c) and insert— maintaining or improving the attractiveness of the relevant part of the United Kingdom as a place in which to conduct clinical trials or supply or manufacture human medicines”
Bill texts 9
- Bill 90 2019-21, as introduceddownload soon
- Bill 90 2019-21 - large font accessible versiondownload soon
- Bill 136 2019-21 (as amended in Committee)download soon
- Bill 136 2019-21 (as amended in Committee) - large font accessible versiondownload soon
- HL Bill 116 (as introduced)download soon
- HL Bill 154 (as amended in Grand Committee)download soon
- HL Bill 163 (as amended on Report)download soon
- Bill 242 2019-21 (Lords Amendments)download soon
- HL Bill 167 Commons amendments, disagreements and amendments in lieudownload soon
Amendments 48
Committee stage — Lords 20
at end insert— In subsection (2)(c), “attractiveness” means the quality of being—
at end insert— In subsection (2), “attractiveness” means—
leave out “have regard to” and insert “act with a view to ensuring”
at end insert— The power under subsection (1) may not be exercised to—
at end insert— In making regulations under subsection (1), the appropriate authority must have regard to the desirability of—
at end insert “for a period of three years beginning with the day on which this Act is passed.”
at beginning insert “the priority of ensuring”
at end insert “, and, in the case of regulations not subject to section 42(6), (7) or (8), must publish with the draft regulations an assessment of their impact on,”
at end insert— the effect of the regulations on the ability of the National Health Service to meet the needs of patients;
after “trials” insert “, promote medical innovation”
at end insert— In making regulations under subsection (1), the appropriate authority must have the objective of safeguarding public health by promoting the availability and supply of human medicines.”
at end insert— Regulations made under subsection (1) are subject, in relation to regulations made by the Secretary of State, to the super-affirmative procedure set out in section (Super-affirmative procedure), in relation to regulations made by a Northern Ireland department, to section (Super-affirmative procedure: Northern Ireland), and, in relation to regulations of the Secretary of State and a Northern Ireland department acting jointly, to both.”
at end insert— the environmental and social impact of such medicines, including their manufacturing.”
leave out paragraph (c) and insert— the likelihood of the relevant part of the United Kingdom being seen as an attractive or favourable place in which to conduct clinical trials or supply human medicines.”
leave out “making regulations under subsection (1)” and insert “considering whether they would”
at end insert— The appropriate authority may only make regulations under subsection (1) if satisfied that they would promote the health and safety of the public.”
at end insert “the safety of human medicines as the overriding consideration.”
leave out paragraph (a) and insert— In making regulations under subsection (1), the appropriate authority must also have regard to the following as secondary considerations—”
at end insert— citizens’ right to access medicines as part of the right to the highest attainable standard of physical and mental health as stated in the International Covenant on Economic, Social and Cultural Rights of 1966;
Report stage — Lords 20
at end insert— Regulations made under subsection (1) that introduce significant new policy or significant changes to existing policy are subject, in relation to regulations made by the Secretary of State, to the super-affirmative procedure set out in section (Super-affirmative procedure), in relation to regulations made by a Northern Ireland department, to section (Super-affirmative procedure: Northern Ireland), and, in relation to regulations of the Secretary of State and a Northern Ireland department acting jointly, to both.”
Insert the following new Clause— “Entitlement of a doctor to prescribe medicinal cannabis products
at end insert— Nothing in this section authorises a disclosure of patient information without the consent of the individual to whom that information relates.”
after “a” insert “relevant”
at end insert— Where regulations under subsection (1) may have an impact on the safety of human medicines, the appropriate authority may make the regulations only if the authority considers that the benefits of doing so outweigh the risks.”
leave out “conduct clinical trials or supply human medicines” and insert “— carry out research relating to human medicines,
leave out “an attractive or” and insert “a”
leave out “they would” and insert “regulations under subsection (1) would contribute to this objective”
leave out subsection (2) and insert— In making regulations under subsection (1), the appropriate authority’s overarching objective must be safeguarding public health.”
Insert the following new Clause— “PART A1
at end insert “, or the use of tissues or cells (within the meanings given by regulation 5(1) of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (S.I. 2007/1523)) in relation to human medicines.”
at end insert— the importance of prioritising the protection of human rights including citizens’ right to access medicines as part of the right to the highest attainable standard of physical and mental health as stated in the International Covenant on Economic, Social and Cultural Rights of 1966;
at end insert— Before making regulations under subsection (1) that may have an impact on the safety of human medicines, the Secretary of State must publish the criteria the appropriate authority will use to determine whether the benefits of laying regulations outweigh the risks.
Leave out “public health” and insert “the health and safety of the public”
at end insert “for a period of three years beginning with the day on which this Act is passed.”
at end insert— the protection of the environment;”
After the first “the” insert “informed”
leave out “for any purpose to do with human medicines” and insert “for the purpose of ensuring patient safety”
at end insert— Where information is disclosed in accordance with subsection (2) such disclosure will only be permitted where—
Insert the following new Clause— “Strategy for tackling vaccination disinformation
3rd reading — Lords 8
leave out “order in its initial form, or a revised draft order” and insert “regulations in their original form, or revised draft regulations”
leave out “order”
leave out “order”
leave out “ an order” and insert “regulations”
leave out “order” and insert “regulations”
leave out “section 11(1), section 17(1) and section 21(1)” and insert “and section 11(1)”
leave out from “subject” to end of line 25 and insert “to the super-affirmative procedure set out in section 51”
leave out from “subject” to end of line 8 and insert “to the super-affirmative procedure set out in section 51”